Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this year. It includes sales from new clients in new therapeutic areas, which not only builds our confidence in the anticipated 31.5% increase in revenue for YE June 2025, but is also positive for FY June 2026.
A contract was reported on 17 March with a brand-new client in the field of Antibody Drug Conjugates (ADCs). ADCs are a promising cancer treatmen ....
